Literature DB >> 9628609

Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma.

D W Lin1, M H Gold, S Ransom, W J Ellis, M K Brawer.   

Abstract

PURPOSE: Among the new approaches to enhance the performance of prostate specific antigen (PSA) testing in a biopsy population is the use of the free-to-total PSA as well as the transition zone density, which is calculated by dividing the PSA by the transition zone volume. We compare these manipulations of the PSA to PSA alone in a biopsy population.
MATERIALS AND METHODS: We evaluated 917 consecutive men who underwent ultrasound guided biopsy for an elevation in serum PSA or abnormality on digital rectal examination. Total PSA was measured using the Tandem-E or Tandem-R method. Prostate gland volume and transition zone were measured with ultrasound and calculated using the prolate ellipsoid formula.
RESULTS: In the overall PSA range 276 men had carcinoma (30.0% of the population), while in the PSA 4.0 to 10.0 ng./ml. range 141 of 477 had cancer (29.6%). Receiver operating characteristics analysis and analysis of variance were performed. In the overall PSA series the Tandem total PSA performed as well as any PSA index to predict carcinoma. In the restricted range of total PSA 4.0 to 10.0 ng./ml. total PSA density as well as transition zone density were more predictive than PSA alone. In both PSA ranges the volume of benign glands was significantly larger than in the prostates exhibiting carcinoma. There was no statistically significant difference in outcomes of analyses between different investigators or different sites of investigation (Veterans Affairs versus university based hospitals).
CONCLUSIONS: In this biopsy population transition zone PSA density did not add to the information available with total PSA and gland volume. Neither investigator nor site bias contributed to the failure of transition zone PSA density or PSA density to predict prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628609     DOI: 10.1016/s0022-5347(01)63036-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  [Transrectal ultrasound of the prostate. Current status and prospects].

Authors:  M Zacharias; K V Jenderka; H Heynemann; P Fornara
Journal:  Urologe A       Date:  2002-11       Impact factor: 0.639

2.  Utility of the transition zone index for identification of prostate cancer in Chinese men with intermediate PSA levels.

Authors:  Ting-yue Qi; Ya-qing Chen; Jun Jiang; Yun-kai Zhu; Xiao-hong Yao; Xiao-jin Wang
Journal:  Int Urol Nephrol       Date:  2012-02-05       Impact factor: 2.370

3.  A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly.

Authors:  K R Swanson; L D True; D W Lin; K R Buhler; R Vessella; J D Murray
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  Prostate specific antigen and acinar density: a new dimension, the "Prostatocrit".

Authors:  Simon Robinson; Marc Laniado; Bruce Montgomery
Journal:  Int Braz J Urol       Date:  2017 Mar-Apr       Impact factor: 1.541

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.